![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 4 of 4. This is the beginning of the thread.
Posted by jrbecker on September 19, 2003, at 16:45:25
18/09/2003 - Eli Lilly and Company
New Research Shows Cymbalta Reduces Anxiety Symptoms Associated with Depression
INDIANAPOLIS--(BUSINESS Significant Improvement Seen as Early as Week 1; Risk of Treatment Emergent Anxiety No Greater Than With Placebo
Business Wire via NewsEdge Corporation : INDIANAPOLIS--(BUSINESS WIRE)--Sept. 18, 2003-- Significant Improvement Seen as Early as Week 1; Risk of Treatment Emergent Anxiety No Greater Than With PlaceboThe investigational drug Cymbalta(tm) (duloxetine HCl) demonstrated rapid relief of anxiety symptoms associated with depression that was sustained for the length of the study period, according to new data published in the journal Depression and Anxiety. In clinical studies, researchers attribute the medication's effect on a broad spectrum of depression symptoms, which include emotional and painful physical symptoms as well as anxiety, to its dual reuptake inhibition of both serotonin and norepinephrine.
"As anxiety is a key symptom of depression, treating this symptom plays a significant role in the overall treatment of depression and in a patient's ability to ultimately achieve complete recovery," said David Dunner, M.D., executive director, University of Washington Center for Anxiety and Depression. "With these patients also at an increased risk for recurrence and suicide, early and effective intervention is critical to the overall health and safety of the patient."
Highlights of this retrospective analysis of four clinical studies include:
-- Cymbalta, in doses of 60 mg and higher, administered once daily, reduced the anxiety symptoms associated with depression when compared to placebo.
-- Depressed patients treated with Cymbalta 60 mg daily showed significant improvements in mean anxiety scores when compared to placebo treated patients.
-- Significant differences were detected as early as week 1 and were sustained throughout the 9 weeks of acute treatment.
-- Cymbalta significantly reduced mean anxiety scores statistically more than did the active comparators (fluoxetine 20 mg or paroxetine 20 mg).
-- Cymbalta-treated patients did not experience treatment emergent anxiety any more often than those taking placebo.
Posted by wsj on September 20, 2003, at 14:11:54
In reply to News -Cymbalta Reduces Anxiety Assoc w Depression , posted by jrbecker on September 19, 2003, at 16:45:25
its not available yet is it?
Posted by SLS on September 20, 2003, at 15:51:38
In reply to Re: News -Cymbalta Reduces Anxiety Assoc w Depression , posted by wsj on September 20, 2003, at 14:11:54
> its not available yet is it?
The PR person at Lilly said that they are hoping for FDA approval before the end of the year. I have read business reports hinting that it might take substantially longer than that, and that Lilly's attempt to get duloxetine approved for both depression and SUI might delay its approval for either. It's all up to the FDA. Lilly seems to have held up their end of the bargain from what I surmise. One way or the other, a more definitive statement will be issued by the FDA before the year is out.
- Scott
Posted by MB on September 20, 2003, at 22:59:16
In reply to News -Cymbalta Reduces Anxiety Assoc w Depression , posted by jrbecker on September 19, 2003, at 16:45:25
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.